Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

Table 2 The mean effectiveness rates and costs of Natalizumab, and Rituximab

Difference in Cost and Effectiveness Rate between Natalizumab and Rituximab
	Natalizumab	Rituximab	Mean difference (95% confidence interval)
Cost of treatment (USD), mean ± SD	50,843.5 ± 32,625.9	15,460.1 ± 12,969.2	35,383.4(25,401.1–49,717.9)
Effectiveness rate (%),^† mean ± SD	72.0 ± 45.4	76.9 ± 42.9	-4.92(-30–27.5)

^† Effectiveness is measured as the reduction in the rate of disease progression as assessed by NEDA-3. Costs included all direct medical costs (e.g., drug acquisition price, lab tests, imaging studies, etc.…) retrieved from the Saudi Ministry of Health cost center

ISSN: 1472-6963